Brain

Can AI learn like us?Can AI learn like us?

Can AI learn like us?

COLD SPRING HARBOR, N.Y., June 20, 2024 /PRNewswire/ -- It reads. It talks. It collates mountains of data and recommends…

11 months ago
The Siegel Rare Neuroimmune Association Creates First-Ever Online Micro-Course for People With Rare Neuroimmune DisordersThe Siegel Rare Neuroimmune Association Creates First-Ever Online Micro-Course for People With Rare Neuroimmune Disorders

The Siegel Rare Neuroimmune Association Creates First-Ever Online Micro-Course for People With Rare Neuroimmune Disorders

The online learning program reflects organization's dedication to empowering individuals and families affected by these conditions with knowledge and supportPOWELL,…

11 months ago
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical TrialClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement NeuronsSOLANA BEACH, Calif., June…

11 months ago
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and DementiaNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced…

11 months ago
Microbot Medical Partners with Brigham and Women’s Hospital for Its Pivotal Human Clinical TrialMicrobot Medical Partners with Brigham and Women’s Hospital for Its Pivotal Human Clinical Trial

Microbot Medical Partners with Brigham and Women’s Hospital for Its Pivotal Human Clinical Trial

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment…

11 months ago
Oragenics, Inc. Announces NYSE American Acceptance of Plan of ComplianceOragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…

11 months ago
Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell TherapyLupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

Drs. Marko Radic and Georg Schett Honored at FOCIS 2024 Meeting SAN FRANCISCO, June 20, 2024 /PRNewswire/ -- The Lupus…

11 months ago
Rutherrin(R) Demonstrates Complete Response in Lung Cancer PreclinicallyRutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

11 months ago
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal EpilepsyNeurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a…

11 months ago